NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ActualEyes, Inc.

ActualEyes, Inc.

Private
JapanHealthcare & Life Scienceshttps://www.actualeyes.co.jp/

Last Round

Series C

Nov 29, 2024

Est. Valuation

$10.47M

Total Funding Raised

$6.81M

Company Overview

ActualEyes, Inc. is a biotechnology company that develops innovative cell therapy and pharmaceutical treatments for corneal endothelial disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyclinical stage biotechregenerative medicinecorneal endothelial diseasescorneal transplant alternativecorneal cell therapyophthalmologybiotechnologyFuchs endothelial corneal dystrophyFECDbullous keratopathypharmaceutical eye dropscorneal regenerationdrug developmentlicensing agreementsSirolimus eye drops

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ActualEyes, Inc. Comparables

Compare ActualEyes, Inc. with similar companies based on industry and business-model similarity.

ActualEyes, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cellusion Inc.
87%
SYSTANE
87%
Trefoil Therapeutics
85%

ActualEyes, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CNov 29, 2024
Series BJun 30, 2022
SeedOct 9, 2019

ActualEyes, Inc. Investors

Notable investors and investment history

ActualEyes, Inc. investors
InvestorRounds
WHIZ Partners, Inc.Seed
Mitsubishi UFJ CapitalSeed
Japan Science and Technology AgencySeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 29, 2024

    $331K round with D. Western Therapeutics Institute and Senju Pharmaceutical.

  • Jun 30, 2022

    $2.4M round led by D. Western Therapeutics Institute, Inc.

ActualEyes, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ActualEyes, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ActualEyes, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersJapan
Employee Range3
Year Founded2018
Last FundingNov 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.